Fluorescent Tumor Agent
Feb 2016Blaze Bioscience Inc.Request Info
SEATTLE, Feb. 26, 2016 — Blaze Bioscience Inc. has announced the BLZ-100 tumor paint for real-time, high-resolution, intraoperative visualization of cancer cells.
The product consists of an optimized peptide and a fluorescent dye, emitting light in the NIR range for more precise, complete resection of cancer throughout surgery.
The investigative agent is in Phase 1 trials, with preclinical utility demonstrated on a range of cancer types.